– NEWLY PUBLISHED STUDY REPORTS INVISIMASK™, A SELF-ADMINISTERED NASAL SPRAY, PROTECTS AGAINST SARS-COV-2 INFECTION FOR UP TO 10 HOURS IN MICE – INVISIMASK HUMAN ANTIBODY NASAL
Emeryville, California, November 9, 2020 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, announced today that
Emeryville, California, October 13, 2020 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced
Emeryville, California, October 5, 2020 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced
Shanghai, China and Emeryville, California, July 20, 2020 – JW Therapeutics, a clinical stage biopharmaceutical company focused on developing, manufacturing and commercializing cell therapies for patients
Emeryville, California, June 25, 2020 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced
Emeryville, California, March 17, 2020 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies for solid tumors, today announced that it has
Emeryville, California, March 3, 2020 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced
Emeryville, California, February 20, 2020 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced
Emeryville, California, February 18, 2020 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced
Alexa Willson has served as the Chief Financial Officer of Eureka Therapeutics since August 2022. Prior to joining the company, She was a Managing Partner of Cloudstone Venture Capital, an early-stage healthtech venture firm since October 2020. Cloudstone is also an investor of Eureka Therapeutics.
Ms. Willson has over 25 years of experience advising public and private companies on corporate finance, strategy, capital raising, valuation, mergers & acquisitions, and other matters. She has founded and run a midmarket investment banking boutique and worked with large Wall Street investment banks, including Kidder Peabody and Drexel Burnham.
Ms. Willson has served on private and non-profit boards and investment committees in various capacities. She teaches financial literacy. Ms. Willson holds a BA from Harvard and an MBA from Stanford Graduate School of Business.